Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
venetoclax + everolimus + Enrylaze
- Development stage
- Unknown
- Lead developer
- Philippe Rousselot
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This investigational combination therapy consists of venetoclax, everolimus, and Enrylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn). It is being evaluated in the ALL-TARGET trial, a Phase 2 precision medicine study led by Philippe Rousselot and the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). The regimen is designed for patients aged 15 and older with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL). The combination targets three critical signaling pathways: BCL-2 (inhibited by venetoclax), mTOR (inhibited by everolimus), and asparagine metabolism (depleted by Enrylaze). Treatment selection in the trial is guided by functional companion drug testing to identify individual patient signaling alterations.
- Other names
- venetoclax + everolimus + crisantaspase recombinant-rywnvenetoclax + everolimus + JZP458
02
Targets
mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on venetoclax + everolimus + Enrylaze.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on venetoclax + everolimus + Enrylaze.